First Author: O.Ruiz-Moreno SPAIN
Co Author(s): P. Calvo B. Abadia J. Leciñena C. Torrón 0 0 0 0 0 0 0 0 0
Back to previous
To evaluate the efficacy and safety of standard-fluence rate photodynamic therapy (PDT) for treating chronic central serous chorioretinopathy.
Retrospective, observational study at Miguel Servet University Hospital, Zaragoza (Spain)
Thirty eyes (30 patients) with chronic central serous chorioretinopathy were retrospectively recorded. PDT was performed using the normal dose (6mg/m2) of verteporfin. A total light energy of 50 J/cm2 over 83 seconds was applied. The laser spot size was the diameter of the region of choroidal hyperpermeability plus 1 mm. The changes in best corrected visual acuity (BCVA) over time, central retinal thickness (CRT) and the rate of eyes with complete subretinal fluid (SRF) reabsorption measured with spectral domain optical coherence tomography (OCT) pre- and post- treatment were analysed.
Mean age was 50 ± 11 years; 26% were women. Post-PDT follow-up ranged from 12 to 39 months (mean 18 months). Mean baseline logarithm of the minimal angle of resolution (logMAR) BCVA was 0.3±0.2 (20/40) and improved significantly (P < 0.001) to 0.2±0.2 (20/32) at 1, 12, and 36 months. Mean CRT was 322.7±64.3µm. SRF resolved in >90% by the last post-PDT visit. Complications were rare, severe visual decrease (>0.3 logMAR units) was not seen in any patient.
In most of the eyes, standard-fluence PDT resulted in visual acuity improvement and complete subretinal fluid reabsorption.